TickerFacts.

Inhibikase Therapeutics, Inc. (IKT): Cash & Equivalents

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$178.80M
As of 2025-12-31
2021-12-31: $40.75M2022-12-31: $7.19M2023-12-31: $9.20M2024-12-31: $97.50M2025-12-31: $178.80M$178.80M
2021-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$178.80M+83.4%2026-03-26, Balance as of period end
2024-12-31$97.50Mn/c2026-03-26, Balance as of period end
2023-12-31$9.20M+28.0%2025-03-27, Balance as of period end
2022-12-31$7.19M-82.4%2024-03-27, Balance as of period end
2021-12-31$40.75Mn/a2023-03-31, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Inhibikase Therapeutics, Inc. (IKT)2025-12-31$178.80M+83.4%
Editas Medicine, Inc. (EDIT)2025-12-31$146.65M+11.5%
Caribou Biosciences, Inc. (CRBU)2025-12-31$12.36M-24.1%
Sutro Biopharma, Inc. (STRO)2025-12-31$58.13M-69.5%
SAB Biotherapeutics, Inc. (SABS)2025-12-31$10.50M+18.0%
Neumora Therapeutics, Inc. (NMRA)2025-12-31$182.53M+28.4%
Aura Biosciences, Inc. (AURA)2025-12-31$59.52M+87.8%
Cabaletta Bio, Inc. (CABA)2025-12-31$82.98M-49.4%
Instil Bio, Inc. (TIL)2025-12-31$6.64M-24.6%

Compare IKT, EDIT, CRBU, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗